Literature DB >> 11425162

Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice.

G V Ludwig1, M J Turell, P Vogel, J P Kondig, W K Kell, J F Smith, W D Pratt.   

Abstract

A candidate live-attenuated virus vaccine for protection against Venezuelan equine encephalitis (VEE) (designated V3526) was tested in mice to measure the magnitude, duration, and kinetics of virus replication in the blood and the central nervous system and its phenotypic stability after multiple passages in mice and cell culture. All results were compared to parallel experiments with parental virus and the existing VEE virus vaccine, TC-83. Maximum virus titers in the brains of V3526-inoculated mice were between 10- and 100-fold less than those observed in brains of mice inoculated intracranially (i.c.) with either the parental virus or TC-83. Neither V3526 nor TC-83 was lethal in BALB/c mice inoculated i.c.. However, mice inoculated with TC-83 developed acute symptoms lasting at least 14 days. In contrast, i.c. inoculation of TC-83 was uniformly lethal for C3H/HeN mice. V3526 was avirulent in both BALB/c and C3H/HeN mice after i.c. inoculation. The virulence characteristics of V3526 remained unchanged after five serial i.c. passages in mouse brains or after five cell culture passages. Finally, pathologic changes induced after i.c. inoculation of V3526 were consistently less severe and of shorter duration than those observed in TC-83-inoculated mice. Based on these results, V3526 is stable and appears to be significantly less neurovirulent in mice than TC-83.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425162     DOI: 10.4269/ajtmh.2001.64.49

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  24 in total

1.  Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.

Authors:  Michael D Parker; Marilyn J Buckley; Vanessa R Melanson; Pamela J Glass; David Norwood; Mary Kate Hart
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Rapid, non-invasive imaging of alphaviral brain infection: reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals.

Authors:  Michael Patterson; Allison Poussard; Katherine Taylor; Alexey Seregin; Jeanon Smith; Bi-Hung Peng; Aida Walker; Jenna Linde; Jennifer Smith; Milagros Salazar; Slobodan Paessler
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

3.  Stability of RNA virus attenuation approaches.

Authors:  Joan L Kenney; Sara M Volk; Jyotsna Pandya; Eryu Wang; Xiaodong Liang; Scott C Weaver
Journal:  Vaccine       Date:  2011-02-01       Impact factor: 3.641

4.  Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine.

Authors:  Justin G Julander; Richard A Bowen; Jagadeeshwar R Rao; Craig Day; Kristiina Shafer; Donald F Smee; John D Morrey; Chung K Chu
Journal:  Antiviral Res       Date:  2008-08-15       Impact factor: 5.970

5.  Biological activities of 'noninfectious' influenza A virus particles.

Authors:  Christopher B Brooke
Journal:  Future Virol       Date:  2014-01       Impact factor: 1.831

6.  In vivo imaging systems (IVIS) detection of a neuro-invasive encephalitic virus.

Authors:  Allison Poussard; Michael Patterson; Katherine Taylor; Alexey Seregin; Jeanon Smith; Jennifer Smith; Milagros Salazar; Slobodan Paessler
Journal:  J Vis Exp       Date:  2012-12-02       Impact factor: 1.355

7.  Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation.

Authors:  Svetlana Atasheva; Dal Young Kim; Maryna Akhrymuk; David G Morgan; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

Review 8.  Vaccines for Venezuelan equine encephalitis.

Authors:  Slobodan Paessler; Scott C Weaver
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

9.  Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic.

Authors:  Slobodan Paessler; Rafik Z Fayzulin; Michael Anishchenko; Ivorlyne P Greene; Scott C Weaver; Ilya Frolov
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  The 5'UTR-specific mutation in VEEV TC-83 genome has a strong effect on RNA replication and subgenomic RNA synthesis, but not on translation of the encoded proteins.

Authors:  Raghavendran Kulasegaran-Shylini; Varatharasa Thiviyanathan; David G Gorenstein; Ilya Frolov
Journal:  Virology       Date:  2009-03-17       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.